A number of developments are translating into a growing demand for mid-scale manufacturing among pharmaceutical and biotech firms. Fragmenting of patient populations through either targeted therapies, more personalized treatment protocols or competing products including biosimilars may require capacities lower than would have been the case in previous years. In addition, the number of therapies addressing unmet needs for niche or orphan indications is increasing, fueled by supportive regulatory systems and buoyant biotech funding. Increased potency of biologic molecules together with more efficient bioprocessing including higher titers and yields are also factors driving the need for mid-scale capacity.
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center